Old tumor samples may hold key to future biliary cancer treatments

NCT ID NCT07515950

Not yet recruiting Knowledge-focused Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Apr 12, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This study will examine stored tumor samples from 244 people diagnosed with biliary tract cancer in the last 15 years. Researchers will measure five specific markers (CLDN18.2, HER2, TROP2, PD-L1, and B7-H4) to see how they relate to patient outcomes. The goal is to better group patients by their cancer type, which could help doctors choose the right targeted therapy in the future. No new treatments or visits are involved—only analysis of existing data and samples.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.